Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) have earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.25.
Several brokerages have recently commented on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. HC Wainwright boosted their price objective on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. TD Cowen cut their price objective on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Tuesday, June 16th.
Get Our Latest Research Report on HUMA
Humacyte Stock Up 14.3%
Humacyte (NASDAQ:HUMA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million. On average, equities analysts predict that Humacyte will post -0.34 EPS for the current fiscal year.
Insider Transactions at Humacyte
In related news, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the insider owned 272,713 shares in the company, valued at $245,441.70. The trade was a 14.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average price of $0.88 per share, with a total value of $49,999.84. Following the transaction, the director directly owned 148,025 shares in the company, valued at $130,262. The trade was a 62.30% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.10% of the stock is owned by insiders.
Hedge Funds Weigh In On Humacyte
Large investors have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new position in Humacyte in the 2nd quarter worth approximately $28,000. Financial Advisors Network Inc. purchased a new position in Humacyte in the 2nd quarter worth approximately $28,000. Cerity Partners LLC purchased a new position in Humacyte in the 2nd quarter worth approximately $35,000. Equitable Holdings Inc. purchased a new position in Humacyte in the 3rd quarter worth approximately $29,000. Finally, Imprint Wealth LLC purchased a new position in Humacyte in the 3rd quarter worth approximately $33,000. 44.71% of the stock is owned by hedge funds and other institutional investors.
About Humacyte
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Read More
- Five stocks we like better than Humacyte
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
